Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics received U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for TN-401, its AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. The designation is backed by interim Phase 1b/2 RIDGE-1 data showing clinically meaningful reductions in daily PVC and NSVT arrhythmia rates with a favorable tolerability profile; TN-401 already holds FDA Fast Track and Orphan Drug designations plus EMA PRIME status. RMAT provides enhanced FDA interactions and potential eligibility for accelerated approval, priority review, and rolling review, with a U.S.
Key figures
- Drug Name
- TN-401
- Phase Of Trial
- Phase 1b/2
- Next catalyst
- additional RIDGE-1 data and update on pivotal-trial regulatory discussions in 4Q 2026
- Pkp2 share of arvc
- approximately 40 percent
- Prior designations
- ["FDA Orphan Drug","FDA Fast Track","EMA PRIME"]
- Us patient prevalence
- more than 70,000
- Ridge1 planned enrollment
- up to fifteen adults
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.